Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 20/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.69 |
| ▸ | SLC2A9 | Q9NRM0 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1299697 | 0.91 | SLC22A12 (0.67) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL249022 | 0.90 | SLC22A12 (0.78) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL11915751 | 0.86 | SLC22A12 (0.71) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL4736111 | 0.85 | SLC22A12 (0.65) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL4735395 | 0.85 | SLC22A12 (0.70) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL12379317 | 0.84 | SLC22A12 (0.71) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL4736147 | 0.84 | SLC22A12 (0.78) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL4736204 | 0.84 | SLC22A12 (0.70) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL19987624 | 0.83 | SLC22A12 (0.79) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 | |
| SCHEMBL4735350 | 0.83 | SLC22A12 (0.82) | SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10351537-B2 | Processes for the preparation of lesinurad and intermediates thereof | APOTEX INC. (CA) | 2019-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351537-B2 | Processes for the preparation of lesinurad and intermediates thereof | LSS, SQOR, PGD | SLC22A12 4221/4885CYP2C9 25/4885CYP2C19 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.